Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that its treatments and technology were featured on the ION Network and Discovery Channel. The news magazine series titled as “NewsWatch,” telecasted the company’s story in a “HealthWatch” segment that covered the company’s initiatives to bring both diabetes and cancer treatments to market.
The expert speaks
Kenneth L. Waggoner, the CEO of Pharmacyte, said that the company is getting attention from all over the nation. HealthWatch performed an impressive job highlighting the entire development story with the level of zeal and attention to detail that company shows in everything it performs. The management is extremely delighted that nearly 96 million households in the United States have had a chance to know about the company’s unique technology. The road to success is showcasing the story in a way that will support getting company’s treatments to patients who are in need of them.
Each episode of NewsWatch is a source for latest consumer, technology, health, travel, and entertainment news. It has been a popular show since 1990 and reaches over 96 million households. As per the stats, so far more than 700 million households have viewed the series, making the show as one of the most successful news magazines on television.
When Pharmacyte first reported that the company’s story will be featured on the channels, the traders rushed in to buy the stock which pushed the stock all the way up to end Monday’s trading session at $0.134 per share. However, the news impact was short-lived as the company is still being pumped. It comes in the list of heavily promoted OTC stocks in 2015. As a result, the stock eroded the previous day gains and declined over 8% in last trading session.
Pharmacyte Biotech Inc (OTCMKTS:PMCB) retraced most of the gains made in the previous session as it finished the last session with a loss of 8.28%. The volume of the day at 4.7 million was almost double the daily average of 2.4 million, indicating the presence of a lot of genuine sellers. The stock has been in a downtrend in all the time frames and this recent rally is running the risk of being negated at the very outset. Any bounce can be expected to be pushed down by the sellers at $0.17 levels but a major support lies there around $0.10.